Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699300 | 0.88 | MTNR1A (0.47) | MTNR1AMTNR1BALDH1A1ACSS2NPC1 | |
| SCHEMBL4693967 | 0.83 | POLB (0.52) | MTNR1AMTNR1BALDH1A1ACSS2 | |
| SCHEMBL6047772 | 0.81 | MC4R (0.43) | MTNR1AMTNR1B | |
| SCHEMBL4766033 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BALDH1A1ACSS2NPC1 | |
| SCHEMBL6047795 | 0.81 | MTNR1A (0.45) | MTNR1AMTNR1B | |
| SCHEMBL4693966 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BACSS2 | |
| SCHEMBL6047881 | 0.80 | MTNR1A (0.41) | MTNR1AMTNR1BACSS2 | |
| SCHEMBL6047818 | 0.80 | MC4R (0.48) | MTNR1AMTNR1B | |
| SCHEMBL4697452 | 0.79 | MTNR1A (0.48) | MTNR1AMTNR1BALDH1A1ACSS2NPC1 | |
| SCHEMBL6047776 | 0.79 | MTNR1A (0.43) | MTNR1AMTNR1BALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | MTNR1A 799/4885MTNR1B 531/4885ALDH1A1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.